External popup 

This site is intended for US healthcare professionals only.

JOURNAVX is now available at major national and select regional retail pharmacies.

SAVINGS AND SUPPORT

 

The JOURNAVX+youTM 
Patient Support
Program

From financial support programs and educational resources to support from JOURNAVX+you Specialists, patients are our priority

JOURNAVX+you

includes the following offerings:

includes the following offerings:

includes the following offerings:

Financial support programs for patients with and without insurance
JOURNAVX+you Specialists for support and information about program offerings
Downloadable educational resources for patients and healthcare providers

JOURNAVXTM SAVINGS CARD

Eligible patients with insurance will pay as little as $30 per fill

 

 

The JOURNAVX Savings Carda can be used by eligible patients with commercial or government-sponsored insurance (such as Medicare, Medicaid, Veterans Affairs, or TRICARE) to support patient access while coverage decisions are being made.

Help your patients save with these 3 steps:

  1. Send the prescription to the patient’s preferred pharmacy (available at major national and select regional retail pharmaciesb)
  2. Ensure that patients with a prescription have a JOURNAVX Savings Card
  3. Patient presents the JOURNAVX Savings Card to the pharmacist

Patients with government-sponsored insurance can only use the JOURNAVX Savings Card when their insurance does not provide coverage for JOURNAVX. For patients whose insurance does not provide coverage for JOURNAVX, using the JOURNAVX Savings Card means a claim will not be submitted through their insurance plan after the card has been redeemed.a

 

 

Download Savings Card

a Select terms and conditions apply:

Commercial Co-pay Assistance for Patients With Commercial Insurance With Coverage for JOURNAVX: For each fill of JOURNAVX, eligible patients will pay as little as $30 in out-of-pocket costs for up to a 30-day supply of JOURNAVX. Patients cannot exceed a 30-day supply per fill and will receive a maximum benefit of up to $100 per fill. Patients are responsible for any out-of-pocket amount that exceeds the maximum benefit. This benefit can be redeemed until the patient reaches up to 60 days’ supply across total fills. Eligibility for this benefit resets every 365 days from the date of first redemption.

2025 Patient Savings Program for Patients With Commercial and Government-Sponsored Insurance Without Coverage for JOURNAVX: For each fill of JOURNAVX, eligible patients will pay as little as $30 in out-of-pocket costs for up to a 30-day supply of JOURNAVX. Patients cannot exceed a 30-day supply per fill and will receive a maximum benefit of up to $2,000 during the program period ending 12/31/2025. Patients are responsible for any out-of-pocket amount that exceeds the maximum benefit. This benefit can be redeemed until the patient reaches up to 60 days’ supply across total fills. The 2025 Patient Savings Program will expire on 12/31/2025.

JOURNAVX financial support offering is not health insurance. Please see the full terms and conditions.

b  Availability at individual stores may vary. Call the pharmacy to make sure they carry JOURNAVX.

FOR UNINSURED PATIENTS

Patient Assistance Program (PAP)

 

 

Uninsured patients may be eligible to receive JOURNAVX at no cost through the Patient Assistance Program.c Patients can apply online at JOURNAVXpap.com and be informed of their approval status. If they meet eligibility requirements, a PAP voucher will be provided for use at the pharmacy.

 

 

c Terms and conditions apply.

LEARN MORE

JOURNAVX+you
brochures

 

Refer to the helpful resources below for more information about JOURNAVX+you.

 

Download the JOURNAVX+you Brochure for Healthcare Providers for details on the support offerings available for your patients.

For healthcare providers

 

Download the JOURNAVX+you Brochure for Patients so your patients can learn more about program offerings.

For patients

If you have questions about the JOURNAVX+you
Patient Support Program or its offerings, call us at
1-833-5VX-PAIN (1-833-589-7246), 8 AM-11 PM EST,
Monday through Friday (excluding holidays), for assistance.

If you have questions about the JOURNAVX+you
Patient Support Program or its offerings, call us at
1-833-5VX-PAIN (1-833-589-7246), 8 AM-11 PM EST,
Monday through Friday (excluding holidays), for assistance.

If you have questions about the JOURNAVX+you Patient Support Program or its offerings, call us at
1-833-5VX-PAIN
(1-833-589-7246),
8 AM-11 PM EST, Monday through Friday (excluding holidays), for assistance.

Learn how to order samples and enroll in the In-Hospital Pilot Program for JOURNAVX.

 

 

 

Experience Programs

See dosing and administration guidelines for patients taking JOURNAVX.

 

 

 

Dosing

IMPORTANT SAFETY INFORMATION & INDICATION

EXPAND

COLLAPSE

INDICATION

JOURNAVX is indicated for the treatment of moderate-to-severe acute pain in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated.

WARNINGS AND PRECAUTIONS

INDICATION

JOURNAVX is indicated for the treatment of moderate-to-severe acute pain in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated.

WARNINGS AND PRECAUTIONS

Increased Risk of Adverse Reactions With Concomitant Use With Strong and Moderate CYP3A Inhibitors: Strong and moderate CYP3A inhibitors increase suzetrigine and its active metabolite exposures, which may cause adverse reactions with JOURNAVX.

Risk of Drug Interactions With Certain CYP3A Substrates: Suzetrigine is an inducer of CYP3A. If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX.

Risk of Drug Interactions With Certain Hormonal Contraceptives: Patients treated with JOURNAVX who are taking concomitant hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX.

Risk of Adverse Reactions in Patients With Moderate and Severe Hepatic Impairment: Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and its active metabolite than those with normal hepatic function, which may increase the risk of JOURNAVX-related adverse reactions.

ADVERSE REACTIONS

Pooled adverse reactions from Trials 1 and 2 that occurred in ≥1% of patients treated with JOURNAVX and at a greater rate than patients treated with placebo were pruritus, muscle spasms, increased blood creatine phosphokinase, and rash. The safety profile of JOURNAVX in Trial 3 was consistent with that observed in Trials 1 and 2.

DRUG INTERACTIONS

Effect of Other Drugs on JOURNAVX

CYP3A Inhibitors: A reduced dose is recommended when coadministered with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit.

Strong and Moderate CYP3A Inducers: Avoid concomitant use of JOURNAVX with strong and moderate CYP3A inducers. Concomitant use of strong or moderate CYP3A inducers results in reduced exposures of suzetrigine and its active metabolite, which may result in reduced JOURNAVX efficacy.

Effect of JOURNAVX on Other Drugs

CYP3A Substrates: Dose adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. Discontinuation of JOURNAVX may increase the exposure of sensitive CYP3A substrates.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on the use of JOURNAVX during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Lactation

There are no data on the presence of suzetrigine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JOURNAVX and any potential adverse effects on the breastfed child from JOURNAVX or from the underlying maternal condition.

Infertility

JOURNAVX may reversibly impact the likelihood of females of reproductive potential to become pregnant while on treatment. Patients using contraceptives should continue to use contraceptives.

Geriatric Use

Based on population pharmacokinetic analyses in patients with ages ranging from 18 to 75 years, age does not have a clinically relevant impact on suzetrigine exposure.

Hepatic Impairment

The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child‑Pugh Class B) than those with normal hepatic function. Avoid use of JOURNAVX in patients with severe hepatic impairment (Child‑Pugh Class C).

Renal Impairment

Avoid use of JOURNAVX in patients with renal impairment of eGFR <15 mL/min.

Please see full Prescribing Information for JOURNAVX.

 

 

Increased Risk of Adverse Reactions With Concomitant Use With Strong and Moderate CYP3A Inhibitors: Strong and moderate CYP3A inhibitors increase suzetrigine and its active metabolite exposures, which may cause adverse reactions with JOURNAVX.

Risk of Drug Interactions With Certain CYP3A Substrates: Suzetrigine is an inducer of CYP3A. If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX.

Risk of Drug Interactions With Certain Hormonal Contraceptives: Patients treated with JOURNAVX who are taking concomitant hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX.

Risk of Adverse Reactions in Patients With Moderate and Severe Hepatic Impairment: Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and its active metabolite than those with normal hepatic function, which may increase the risk of JOURNAVX-related adverse reactions.

ADVERSE REACTIONS

Pooled adverse reactions from Trials 1 and 2 that occurred in ≥1% of patients treated with JOURNAVX and at a greater rate than patients treated with placebo were pruritus, muscle spasms, increased blood creatine phosphokinase, and rash. The safety profile of JOURNAVX in Trial 3 was consistent with that observed in Trials 1 and 2.

DRUG INTERACTIONS

Effect of Other Drugs on JOURNAVX

CYP3A Inhibitors: A reduced dose is recommended when coadministered with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit.

Strong and Moderate CYP3A Inducers: Avoid concomitant use of JOURNAVX with strong and moderate CYP3A inducers. Concomitant use of strong or moderate CYP3A inducers results in reduced exposures of suzetrigine and its active metabolite, which may result in reduced JOURNAVX efficacy.

Effect of JOURNAVX on Other Drugs

CYP3A Substrates: Dose adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. Discontinuation of JOURNAVX may increase the exposure of sensitive CYP3A substrates.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on the use of JOURNAVX during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Lactation

There are no data on the presence of suzetrigine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JOURNAVX and any potential adverse effects on the breastfed child from JOURNAVX or from the underlying maternal condition.

Infertility

JOURNAVX may reversibly impact the likelihood of females of reproductive potential to become pregnant while on treatment. Patients using contraceptives should continue to use contraceptives.

Geriatric Use

Based on population pharmacokinetic analyses in patients with ages ranging from 18 to 75 years, age does not have a clinically relevant impact on suzetrigine exposure.

Hepatic Impairment

The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child‑Pugh Class B) than those with normal hepatic function. Avoid use of JOURNAVX in patients with severe hepatic impairment (Child‑Pugh Class C).

Renal Impairment

Avoid use of JOURNAVX in patients with renal impairment of eGFR <15 mL/min.

Please see full Prescribing Information for JOURNAVX.

 

INDICATION

JOURNAVX is indicated for the treatment of moderate-to-severe acute pain in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated.

WARNINGS AND PRECAUTIONS

Increased Risk of Adverse Reactions With Concomitant Use With Strong and Moderate CYP3A Inhibitors: Strong and moderate CYP3A inhibitors increase suzetrigine and its active metabolite exposures, which may cause adverse reactions with JOURNAVX.

Risk of Drug Interactions With Certain CYP3A Substrates: Suzetrigine is an inducer of CYP3A. If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX.

Risk of Drug Interactions With Certain Hormonal Contraceptives: Patients treated with JOURNAVX who are taking concomitant hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX.

Risk of Adverse Reactions in Patients With Moderate and Severe Hepatic Impairment: Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and its active metabolite than those with normal hepatic function, which may increase the risk of JOURNAVX-related adverse reactions.

ADVERSE REACTIONS

Pooled adverse reactions from Trials 1 and 2 that occurred in ≥1% of patients treated with JOURNAVX and at a greater rate than patients treated with placebo were pruritus, muscle spasms, increased blood creatine phosphokinase, and rash. The safety profile of JOURNAVX in Trial 3 was consistent with that observed in Trials 1 and 2.

DRUG INTERACTIONS

Effect of Other Drugs on JOURNAVX

CYP3A Inhibitors: A reduced dose is recommended when coadministered with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit.

Strong and Moderate CYP3A Inducers: Avoid concomitant use of JOURNAVX with strong and moderate CYP3A inducers. Concomitant use of strong or moderate CYP3A inducers results in reduced exposures of suzetrigine and its active metabolite, which may result in reduced JOURNAVX efficacy.

Effect of JOURNAVX on Other Drugs

CYP3A Substrates: Dose adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. Discontinuation of JOURNAVX may increase the exposure of sensitive CYP3A substrates.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on the use of JOURNAVX during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Lactation

There are no data on the presence of suzetrigine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JOURNAVX and any potential adverse effects on the breastfed child from JOURNAVX or from the underlying maternal condition.

Infertility

JOURNAVX may reversibly impact the likelihood of females of reproductive potential to become pregnant while on treatment. Patients using contraceptives should continue to use contraceptives.

Geriatric Use

Based on population pharmacokinetic analyses in patients with ages ranging from 18 to 75 years, age does not have a clinically relevant impact on suzetrigine exposure.

Hepatic Impairment

The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child‑Pugh Class B) than those with normal hepatic function. Avoid use of JOURNAVX in patients with severe hepatic impairment (Child‑Pugh Class C).

Renal Impairment

Avoid use of JOURNAVX in patients with renal impairment of eGFR <15 mL/min.

Please see full Prescribing Information for JOURNAVX.